Nrx Pharmaceuticals Inc (NRXP) Stock Price, Quote & News

Company Profile

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-f...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 254 6134

Website: www.nrxpharma.com

Address:

1201 Orange Street, Suite 600, Wilmington, United States

Ichigodoran Dec. 4 at 5:53 PM

New analyst report from D. Boral Capital - NRx Pharmaceuticals Advances NRX-101 Into New TMS Augmentation Indication Read Report - https://nrxpharma.com/wp-content/uploads/2025/12/NRx-Pharmaceuticals-Advances-NRX-101-Into-New-TMS-Augmentation.pdf #PharmaNews #depression #ketamine #stress #PTSD #bipolar #psychiatry #healthcare #clinic #NRXPharma #HopeTherapeutics $NRXP

2 · Reply

MoneyGroupLLC Dec. 4 at 5:38 PM

Enter: $NRXP Calls Strike Price: $2 Expiry Date: JAN 16 2026 Buy in Price: $0.83 - $3.60 Sell Price: $1.34 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Ihavesunshineinmypocket Dec. 4 at 5:34 PM

$NRXP

0 · Reply

ClenchFists Dec. 4 at 5:09 PM

$NRXP NRX-101 PDUFA this december!!! Let's goooo!!!

2 · Reply

systemish Dec. 4 at 4:47 PM

$NRXP Management has a one year to get something/anything done because MAGA will not survive the mid-terms and all the benefits espoused over the last year will reverse. Do we have an answer on the expiration of publicly traded warrants? Are they toast in a few months?

1 · Reply

flybyme Dec. 4 at 4:41 PM

$NRXP another price target, don't read them anymore, waste of time, results are what count JJ, Hard core news is what we want not a pump.

1 · Reply

Im_Trying Dec. 4 at 4:22 PM

$NRXP needs a few fireside chats to get this thing really going

2 · Reply

jonny80s Dec. 4 at 4:13 PM

$NRXP going to have to have some decent news to get this back in the $3 range. How’s that “coming weeks NDA submission” coming along?

1 · Reply

Drerekcohert90 Dec. 4 at 4:11 PM

$NRXP I think this is the next $CAPR two months or less will see

1 · Reply

SmallCapGrowth Dec. 4 at 1:02 PM

NRx Pharmaceuticals $NRXP Amends IND to Advance NRX-101 With TMS for Depression Treatment https://www.reddit.com/r/nasdaq/comments/1pdzcrt/nrx_pharmaceuticals_nrxp_amends_ind_to_advance/ @frontpagestocks

1 · Reply

NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation

Dec 2, 2025, 11:23 AM EST - 2 days ago

NRx Pharmaceuticals, Inc. (NRXP) Discusses Regulatory Update and Development Pipeline Expansion for Preservative-Free Ketamine Formulation Transcript

Dec 2, 2025, 8:30 AM EST - 2 days ago

NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine

Dec 2, 2025, 7:30 AM EST - 2 days ago

NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call

Dec 1, 2025, 8:03 AM EST - 3 days ago

NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference

Nov 17, 2025, 11:57 AM EST - 17 days ago

NRx Pharmaceuticals, Inc. (NRXP) Q3 2025 Earnings Call Transcript

Nov 17, 2025, 8:03 AM EST - 17 days ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 8:31 AM EST - 22 days ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025

Nov 10, 2025, 8:03 AM EST - 24 days ago

HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health

Oct 20, 2025, 8:03 AM EDT - 6 weeks ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director

Oct 6, 2025, 8:03 AM EDT - 2 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference

Sep 29, 2025, 8:03 AM EDT - 2 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine

Sep 24, 2025, 8:03 AM EDT - 2 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine

Sep 8, 2025, 8:17 AM EDT - 3 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics

Sep 3, 2025, 8:03 AM EDT - 3 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th

Sep 2, 2025, 1:19 PM EDT - 3 months ago

UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller, Sponsored by Rockefeller Global Family Office

Sep 2, 2025, 8:41 AM EDT - 3 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital

Aug 27, 2025, 8:03 AM EDT - 3 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)

Aug 20, 2025, 12:23 PM EDT - 3 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q2 2025 Earnings Call Transcript

Aug 18, 2025, 8:10 AM EDT - 3 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 6:06 PM EDT - 4 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

Aug 11, 2025, 4:05 PM EDT - 4 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

Aug 11, 2025, 8:03 AM EDT - 4 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression

Aug 8, 2025, 8:03 AM EDT - 4 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA)

Aug 4, 2025, 8:03 AM EDT - 4 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of a Citizen Petition with the US Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products

Jul 29, 2025, 8:03 AM EDT - 4 months ago

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join Fireside Chat at BTIG Virtual Biotech Conference July 29 - 30, 2025

Jun 26, 2025, 8:03 AM EDT - 5 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics

Jun 23, 2025, 8:03 AM EDT - 5 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)

Jun 16, 2025, 8:03 AM EDT - 6 months ago

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners

Jun 12, 2025, 8:03 AM EDT - 6 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 5, 2025, 8:03 AM EDT - 6 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine

May 16, 2025, 8:46 PM EDT - 7 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript

May 15, 2025, 4:03 PM EDT - 7 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 10:15 AM EDT - 7 months ago

HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions

May 13, 2025, 8:03 AM EDT - 7 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics

May 12, 2025, 8:03 AM EDT - 7 months ago

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025

May 6, 2025, 8:03 AM EDT - 7 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025

May 5, 2025, 8:03 AM EDT - 7 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine

Apr 30, 2025, 8:46 AM EDT - 7 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression

Apr 21, 2025, 8:01 AM EDT - 8 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025

Apr 3, 2025, 8:03 AM EDT - 8 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE

Mar 31, 2025, 8:02 AM EDT - 8 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics

Mar 24, 2025, 8:02 AM EDT - 9 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics

Mar 17, 2025, 10:50 AM EDT - 9 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 8:02 AM EDT - 9 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 8:01 AM EDT - 9 months ago

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 17, 2025

Feb 6, 2025, 8:03 AM EST - 10 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025

Feb 3, 2025, 8:59 AM EST - 10 months ago

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor

Jan 28, 2025, 8:05 AM EST - 11 months ago

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition

Jan 28, 2025, 8:03 AM EST - 11 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt

Ichigodoran Dec. 4 at 5:53 PM

2 · Reply

MoneyGroupLLC Dec. 4 at 5:38 PM

0 · Reply

Ihavesunshineinmypocket Dec. 4 at 5:34 PM

$NRXP

0 · Reply

ClenchFists Dec. 4 at 5:09 PM

$NRXP NRX-101 PDUFA this december!!! Let's goooo!!!

2 · Reply

systemish Dec. 4 at 4:47 PM

1 · Reply

flybyme Dec. 4 at 4:41 PM

$NRXP another price target, don't read them anymore, waste of time, results are what count JJ, Hard core news is what we want not a pump.

1 · Reply

Im_Trying Dec. 4 at 4:22 PM

$NRXP needs a few fireside chats to get this thing really going

2 · Reply

jonny80s Dec. 4 at 4:13 PM

$NRXP going to have to have some decent news to get this back in the $3 range. How’s that “coming weeks NDA submission” coming along?

1 · Reply

Drerekcohert90 Dec. 4 at 4:11 PM

$NRXP I think this is the next $CAPR two months or less will see

1 · Reply

SmallCapGrowth Dec. 4 at 1:02 PM

1 · Reply

HedgeAlerts Dec. 4 at 7:46 AM

Hedge Alert Live - Protect Your Portfolio Contract: $NRXP $2.50 Put · DEC 19, 2025 Exp Entry Price: $0.35 - $0.50 Exit Price Target: $0.65 Profit Margin: +85% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

TravisBking87 Dec. 3 at 10:21 PM

$CAPR you missed this do not miss the next big one really big one and it most likely going to be $NRXP

1 · Reply

Paulisdead Dec. 3 at 10:20 PM

$NRXP it’s ‘news’ is always filing amended paperwork, with the FDA presenting at an investor conference, and some reprint of an analyst pump & dump from a third rate investment firm. Wake up this bag holder when there’s news that drives revenue and profits.

0 · Reply

alwaysWinVlmr Dec. 3 at 9:23 PM

$NRXP

0 · Reply

geegor Dec. 3 at 8:43 PM

$NRXP Does somebody at NRXP have a private hotline to D Boral Capital, or a friend working there? I have never seen a price target on a stock updated and reissued on such a regular basis. Whenever there is any SP weakness, all of a sudden D Boral Capital puts out an identical update on its PT and maintaining a Buy recommendation to the newswires. It's becoming so regular now it's comical 🤣

2 · Reply

BlazingStocks Dec. 3 at 8:33 PM

$NRXP - NRx has amended its Investigational New Drug filing for NRX-101 (D-cycloserine/lurasidone) to include its use in association with TMS for the treatment of depression, including suicidal depression. This protocol will be available to patients both through a clinical trial and under NRx’s Expanded Access protocols. https://finance.yahoo.com/news/nrx-pharmaceuticals-discuss-nrx-101-120000053.html

0 · Reply

flybyme Dec. 3 at 8:30 PM

$NRXP so many Targets and what hapeens , Nothing

0 · Reply

JarvisFlow Dec. 3 at 8:27 PM

D. Boral Capital updates rating for NRX Pharmaceuticals ( $NRXP ) to Buy, target set at 34.

1 · Reply

dontfeedthebashers Dec. 3 at 7:37 PM

$NRXP

0 · Reply

prismmarketview Dec. 3 at 7:09 PM

NRx Pharmaceuticals (NASDAQ: $NRXP) is advancing NRX‑101 into a new Phase 3 program as an add‑on to transcranial magnetic stimulation for major depressive disorder, aiming to boost TMS response and remission rates while expanding its psychiatric pipeline into treatment‑resistant depression. https://prismmarketview.com/nrx-advances-nrx-101-into-a-new-phase-3-program-as-an-add-on-to-tms-expanding-its-psychiatric-pipeline/

0 · Reply

Sookie1962 Dec. 3 at 6:52 PM

$NRXP down she gos

0 · Reply

BlazingStocks Dec. 3 at 5:51 PM

$NRXP - As previously announced, low dose D-cycloserine has been associated with augmentation of the antidepressant and antisuicidal response achieved by Transcranial Magnetic Stimulation (TMS). https://finance.yahoo.com/news/nrx-pharmaceuticals-discuss-nrx-101-120000053.html

0 · Reply

Market Cap	63.78M
Revenue (ttm)	0.00
Net Income (ttm)	-25.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.39

Volume	356,600
Avg Vol	451,894
Day's Range	N/A - N/A
Shares Out	28.10M
Stochastic %K	83%
Beta	1.91
Analysts	Strong Sell
Price Target	$36.50